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OBJECTIVE—To determine the individual persistence of the relationship between mean
sensor glucose (MG) concentrations and hemoglobin A1c (A1C) from the Juvenile Diabetes Re-
search Foundation Continuous Glucose Monitoring (CGM) Randomized Trial.
RESEARCH DESIGN AND METHODS—MG was calculated using CGM data for
3 months before A1C measurements at 3, 6, 9, and 12 months for the CGM group and at
9and12monthsforthecontrolgroup.AnMG-to-A1Cratiowasincludedinanalysisforsubjects
who averaged $4 days/week of CGM use.
RESULTS—Spearman correlations of the MG-to-A1C ratio between consecutive visits 3 months
apart ranged from 0.70 to 0.79. The correlations for children and youth were slightly smaller than
those for adults. No meaningful differences were observed by device type or change in A1C.
CONCLUSIONS—Individual variations in the rate of hemoglobin glycation are persistent
and contribute to the inaccuracy in estimating MGs calculated from A1C levels.
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H
emoglobinA1c(A1C)isatime-hon-
ored gold standard measure of
overall diabetes control, and A1C
measurements serve as the targets for di-
abetes management (1). More recently,
elevated A1C has been proposed as a
more facile method for diagnosing diabe-
tes (2). Additionally, A1C forms the basis
for calculating the synthetic estimated
average glucose (eAG) (3). Both of these
uses of A1C implicitly assume a consis-
tent ratio between A1C and mean glucose
(MG) over 2–3 months across individual
subjects. Although the chemistry of gly-
cation predicts a straightforward relation-
ship between MG concentrations and
A1C, many investigators have reported
persistent individual variations in the rate
of glycation among both subjects with
and without diabetes. Investigators have
described fast or high glycators as well
as slow or low glycators. Twin studies
suggest a substantial heritable compo-
nent (4).
Quantifying both the magnitude and
the degree of persistence of the individual
variation in the rate of erythrocyte glyca-
tion, however, has been hampered by
limitations in accessing MG concentra-
tions in groups of patients over a long
period of time (5,6). In contrast, the re-
cently completed Juvenile Diabetes Re-
search Foundation (JDRF) Continuous
Glucose Monitoring (CGM) trial provided
data to closely examine the relationship
between MG concentrations, measured
in a near continuous fashion for 6–
12months,andtheA1Cvaluesmeasured
centrally in the Diabetes Control and
Complications Trial/Epidemiology of
Diabetes Interventions and Complica-
tions (DCCT/EDIC) laboratory in pa-
tients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS—The JDRF CGM random-
ized trial protocol has been described in
detail previously (7–9). Major eligibility
criteria included age $8 years, type 1 di-
abetesfor$1year,useofeitheraninsulin
pump or at least three daily insulin injec-
tions, and A1C ,10.0%. Subjects were
randomlyassignedtoeitheraCGMgroup
or a control group for the ﬁrst 6 months
after which both groups used CGM for
an additional 6 months. A1C was mea-
sured, and CGM data were downloaded
at study visits occurring at 3, 6, 9, and
12 months from baseline. Thus subjects
in the CGM group could contribute up to
fourA1C/CGMdatapointsover12months,
whereas those in the original control
group could contribute two data points
(when they had been using CGM at the
9- and 12-month visits).
All three commercially available glu-
cose sensors were used, and subjects were
instructed to wear the sensor on a contin-
uousbasis(7,8).Anewsensorwasinserted
every 3–7da yswi t h4 –15calibrationsover
the sensor use according to the manufac-
turer’srecommendations.A1Cvalueswere
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using the Tosoh A1C2.2 PlusGlycohemo-
globin high-performance liquid chroma-
tography analyzer (9).
MG was calculated using CGM data
over the 91-day span before each visit,
giving equal weight to each of the 24 h of
the day. A data point was included in the
analysis if the subject averaged $4 days
per week of CGM use over the 91-day
period and the subject had at least two
3-month CGM epochs followed by an
A1C value. This criterion was met for
889epochsin311ofthe451randomized
subjects (153 had two epochs, 49 had
three epochs, and 109 had four epochs).
Within-subject persistency of the ratio of
MG to A1C at different time points was
assessed using Spearman correlation. A
correlation coefﬁcient based on ranks us-
ing the method of Magee (10) to account
for repeated measures was computed.
Results were similar using the hemoglo-
bin glycation index (11) as an alternate
measure of glycation, using both the re-
gression equations from the JDRF ran-
domized clinical trial data (7,8) and the
American Diabetes Association Equation
(12) (Supplementary Figs. A1 and A2).
Subgroup analyses were performed by age,
sex, device type, and change in A1C over
the previous 3 months. The cohort did not
contain enough non-White or Hispanic
subjects to evaluate race/ethnicity.
RESULTS—The 311 subjects ranged in
age from 8 to 73 years (mean 6 SD: 28 6
17) at study entry, with 28% of subjects
aged8to,15years,26%between15and
,25 years, and 46% $25 years. Median
(25th, 75th percentiles) duration of dia-
betes was 6 (3, 7), 8 (5, 12), and 23 (16,
32) years for these age-groups, respec-
tively. Baseline A1C values ranged from
4.7 to 9.8% (mean 6 SD: 7.4 6 0.8),
and 56% were female.
The median (25th, 75th percentiles)
of the MG-to-A1C ratio among all 889
epochs was 22.2 mg/dL per 1% (20.8,
23.5) ranging from 17.2 to 31.6. This
distribution was steady over the 12-month
course of the study (median values 22.4,
22.1, 22.1, and 22.1 at 3, 6, 9, and 12
months, respectively). Children and
youth had larger ratios compared with
adults (median 23.0 vs. 22.3 vs. 21.4
for subjects aged 8 to ,15, 15 to ,25,
and $25 years, respectively; P , 0.001).
AsshowninFig.1,subjectswhowere
high glycators (low MG-to-A1C ratio)
during one 3-month epoch tended to
be high glycators during the subsequent
3-month epoch. Correlations of the MG-
to-A1C ratio between consecutive epochs
rangedfrom0.70to0.79.The correlation
value from the repeated-measures model
was0.67.Thecorrelationwascomparable
(r = 0.75) over a 9-month span from 3 to
12 months. Correlation values for chil-
dren and youth were smaller than those
in adults ranging from 0.57 to 0.71, 0.46
to0.65,and0.75to0.78betweenconsec-
utive epochs, for subjects aged 8 to ,15,
15 to ,25, and $25 years, respectively.
AllPvalueswere,0.001.Correlationsof
the ratio of change in MG to change in
A1C between successive visits ranged
from 0.50 to 0.58 (Supplementary Fig.
A3). No meaningful differences were
observed by sex, device type, and treat-
ment group (Supplementary Table A1
and Fig. A4).
CONCLUSIONS—Our results con-
ﬁrm the ﬁnding of others that individuals
with type 1 diabetes persistently glycate
hemoglobinatdifferentrates. Many factors
havebeenproposedtoexplainthis(13,14),
including conditions impacting erythro-
cyte life span, variation in erythrocyte glu-
cose transport, and deglycation within the
erythrocytes. In a recent meta-analysis of
10 genome-wide association studies ex-
amining nearly 15,000 nondiabetic adults
of European descent, Wheeler et al. (15)
found 10 loci associated with A1C, 2 of
which were associated with iron homeo-
stasis, perhapsalteringerythrocyte lifespan.
Factors that alter the rate of hemo-
globin glycation may be associated with
the rate of glycation of other proteins,
thus impacting the likelihood of diabetes
complications. Additionally, these per-
sistantdifferencesintheMG-to-A1Cratio
imply that the MG concentration calcu-
lated from A1C measurement should be
used with caution.
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